Join to View Full Profile
600 Highland AveMadison, WI 53792
Phone+1 608-265-1700
Fax+1 608-262-1982
Dr. Holen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1996 - 1999
Columbia University Vagelos College of Physicians and SurgeonsClass of 1996
Certifications & Licensure
IL State Medical License 2002 - 2017
WI State Medical License 2002 - 2015
Clinical Trials
- Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas Start of enrollment: 2004 Jul 01
- Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
- AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Start of enrollment: 2008 Nov 07
- Join now to see all
Publications & Presentations
PubMed
- 28 citationsComparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with GlioblastomaAndrew B. Lassman, Lisa Roberts-Rapp, Sokolova Irina A, Minghao Song, Ekaterina Pestova
Clinical Cancer Research. 2019-06-01 - 84 citationsSafety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicente...Andrew B. Lassman, Martin J. van den Bent, Hui K Gan, David A. Reardon, Priya Kumthekar
Neuro-Oncology. 2019-01-01 - 57 citationsSafety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.Hui K Gan, David A. Reardon, Andrew B. Lassman, Ryan Merrell, Martin J. van den Bent
Neuro-Oncology. 2018-05-18
Press Mentions
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual MeetingMay 19th, 2023- New Skin Cancer Vaccine Cuts Risk of Relapse by 44%, Study Shows—Here’s What to KnowApril 22nd, 2023
- Skin Cancer: Vaccine May Help Prevent It from ReturningApril 19th, 2023
- Join now to see all
Grant Support
- Phase II Trial Of Bevacizumab And Erlotinib In Advanced Biliary TumorsNational Center For Research Resources2007
- Phase II Study Of Bevacizumab PLUS Erlotinib In Advanced Hepatocellular CancerNational Center For Research Resources2007
- Phase II Study Of Triapine For Advanced Adenocarcinoma Of The PancreasNational Center For Research Resources2006
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
